Literature DB >> 18052981

Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation.

Fei Liu1, Bin Li, E-Jan Tung, Inge Grundke-Iqbal, Khalid Iqbal, Cheng-Xin Gong.   

Abstract

Microtubule-associated protein tau is abnormally hyperphosphorylated and aggregated into neurofibrillary tangles in brains with Alzheimer's disease. The phosphorylation sites of tau are mainly localized in the proline-rich (residues 172-251) and C-terminal tail (residues 368-441) regions, which flank the microtubule-binding repeats. Here, we investigated the effects of tau phosphorylation at these distinct sites/regions on its activity of stimulating microtubule assembly and its self-aggregation. We found that tau phosphorylation at the proline-rich region by dual-specificity tyrosine-phosphorylated and -regulated kinase 1A inhibited its microtubule assembly activity moderately and promoted its self-aggregation slightly. Tau phosphorylation at the C-terminal tail region by glycogen synthase kinase-3beta increased its activity and promoted its self-aggregation markedly. Tau phosphorylation at both regions plus the microtubule-binding region by cAMP-dependent protein kinase diminished its activity (approximately 70% inhibition) and disrupted microtubules. These studies reveal the differential regulation of tau's biological activity and self-aggregation by phosphorylation at various sites/regions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18052981      PMCID: PMC2262108          DOI: 10.1111/j.1460-9568.2007.05955.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  46 in total

1.  The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase.

Authors:  Y L Woods; P Cohen; W Becker; R Jakes; M Goedert; X Wang; C G Proud
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

2.  Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease.

Authors:  Thomas Fath; Jochen Eidenmüller; Roland Brandt
Journal:  J Neurosci       Date:  2002-11-15       Impact factor: 6.167

3.  Granular tau oligomers as intermediates of tau filaments.

Authors:  Sumihiro Maeda; Naruhiko Sahara; Yuko Saito; Miyuki Murayama; Yuji Yoshiike; Hyonchol Kim; Tomohiro Miyasaka; Shigeo Murayama; Atsushi Ikai; Akihiko Takashima
Journal:  Biochemistry       Date:  2007-03-06       Impact factor: 3.162

Review 4.  Post-translational modifications of tau protein in Alzheimer's disease.

Authors:  C-X Gong; F Liu; I Grundke-Iqbal; K Iqbal
Journal:  J Neural Transm (Vienna)       Date:  2004-10-27       Impact factor: 3.575

5.  The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains.

Authors:  J Biernat; E M Mandelkow
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

6.  PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.

Authors:  Fei Liu; Zhihou Liang; Jianhua Shi; Dongmei Yin; Ezzat El-Akkad; Inge Grundke-Iqbal; Khalid Iqbal; Cheng-Xin Gong
Journal:  FEBS Lett       Date:  2006-10-24       Impact factor: 4.124

7.  TMAO promotes fibrillization and microtubule assembly activity in the C-terminal repeat region of tau.

Authors:  Francesca Scaramozzino; Dylan W Peterson; Patrick Farmer; J T Gerig; Donald J Graves; John Lew
Journal:  Biochemistry       Date:  2006-03-21       Impact factor: 3.162

8.  Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model.

Authors:  Y P Wang; J Biernat; M Pickhardt; E Mandelkow; E-M Mandelkow
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

9.  C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease.

Authors:  A Abraha; N Ghoshal; T C Gamblin; V Cryns; R W Berry; J Kuret; L I Binder
Journal:  J Cell Sci       Date:  2000-11       Impact factor: 5.285

10.  Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.

Authors:  M Goedert; M G Spillantini; M C Potier; J Ulrich; R A Crowther
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

View more
  81 in total

Review 1.  Human fetal tau protein isoform: possibilities for Alzheimer's disease treatment.

Authors:  Nataša Jovanov-Milošević; Davor Petrović; Goran Sedmak; Mario Vukšić; Patrick R Hof; Goran Simić
Journal:  Int J Biochem Cell Biol       Date:  2012-05-15       Impact factor: 5.085

Review 2.  14-3-3/Tau Interaction and Tau Amyloidogenesis.

Authors:  Yuwen Chen; Xingyu Chen; Zhiyang Yao; Yuqi Shi; Junwen Xiong; Jingjing Zhou; Zhengding Su; Yongqi Huang
Journal:  J Mol Neurosci       Date:  2019-05-06       Impact factor: 3.444

3.  Pseudophosphorylation of tau protein directly modulates its aggregation kinetics.

Authors:  Edward Chang; Sohee Kim; Kelsey N Schafer; Jeff Kuret
Journal:  Biochim Biophys Acta       Date:  2010-10-23

4.  Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells.

Authors:  Steven J Greco; Sraboni Sarkar; Gemma Casadesus; Xiongwei Zhu; Mark A Smith; J Wesson Ashford; Jane M Johnston; Nikolaos Tezapsidis
Journal:  Neurosci Lett       Date:  2009-03-25       Impact factor: 3.046

5.  Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells.

Authors:  Steven J Greco; Sraboni Sarkar; Jane M Johnston; Xiongwei Zhu; Bo Su; Gemma Casadesus; J Wesson Ashford; Mark A Smith; Nikolaos Tezapsidis
Journal:  Biochem Biophys Res Commun       Date:  2008-09-16       Impact factor: 3.575

6.  Inhibition of cyclin-dependent kinase 5 but not of glycogen synthase kinase 3-β prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes.

Authors:  Horacio Maldonado; Eugenio Ramírez; Elias Utreras; María E Pando; Ana M Kettlun; Mario Chiong; Ashok B Kulkarni; Lucía Collados; Javier Puente; Luis Cartier; María A Valenzuela
Journal:  J Neurosci Res       Date:  2011-06-10       Impact factor: 4.164

7.  Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.

Authors:  David J Irwin; Todd J Cohen; Murray Grossman; Steven E Arnold; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski
Journal:  Brain       Date:  2012-03       Impact factor: 13.501

8.  Effect of Phosphorylation and O-GlcNAcylation on Proline-Rich Domains of Tau.

Authors:  Lata Rani; Jeetain Mittal; Sairam S Mallajosyula
Journal:  J Phys Chem B       Date:  2020-03-02       Impact factor: 2.991

Review 9.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

10.  Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases.

Authors:  Yang Yu; Xiaoqin Run; Zhihou Liang; Yi Li; Fei Liu; Ying Liu; Khalid Iqbal; Inge Grundke-Iqbal; Cheng-Xin Gong
Journal:  J Neurochem       Date:  2009-01-13       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.